22,771 Shares in Exact Sciences Co. (NASDAQ:EXAS) Acquired by Grandfield & Dodd LLC

Grandfield & Dodd LLC bought a new stake in shares of Exact Sciences Co. (NASDAQ:EXAS - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 22,771 shares of the medical research company's stock, valued at approximately $1,685,000.

A number of other hedge funds also recently modified their holdings of the company. Norges Bank acquired a new stake in shares of Exact Sciences in the 4th quarter valued at $47,037,000. Capital World Investors increased its holdings in Exact Sciences by 17.2% in the first quarter. Capital World Investors now owns 5,487,009 shares of the medical research company's stock valued at $383,652,000 after purchasing an additional 804,159 shares during the last quarter. Vanguard Group Inc. increased its holdings in Exact Sciences by 4.4% in the third quarter. Vanguard Group Inc. now owns 16,676,611 shares of the medical research company's stock valued at $541,823,000 after purchasing an additional 698,740 shares during the last quarter. Artisan Partners Limited Partnership increased its holdings in Exact Sciences by 11.8% in the third quarter. Artisan Partners Limited Partnership now owns 3,961,514 shares of the medical research company's stock valued at $270,254,000 after purchasing an additional 418,770 shares during the last quarter. Finally, Qube Research & Technologies Ltd increased its holdings in Exact Sciences by 328.3% in the third quarter. Qube Research & Technologies Ltd now owns 540,191 shares of the medical research company's stock valued at $36,852,000 after purchasing an additional 414,059 shares during the last quarter. Institutional investors own 88.82% of the company's stock.

Analysts Set New Price Targets

Several research firms have recently weighed in on EXAS. TheStreet cut Exact Sciences from a "c-" rating to a "d+" rating in a research report on Monday, February 26th. Canaccord Genuity Group reduced their price target on Exact Sciences from $100.00 to $90.00 and set a "buy" rating on the stock in a research report on Thursday, February 22nd. William Blair reaffirmed an "outperform" rating on shares of Exact Sciences in a report on Thursday, February 22nd. Benchmark raised Exact Sciences from a "hold" rating to a "buy" rating and set a $91.00 price objective on the stock in a report on Tuesday, January 2nd. Finally, Citigroup reaffirmed a "buy" rating and set a $100.00 target price on shares of Exact Sciences in a research report on Wednesday, April 3rd. Three equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat, Exact Sciences has an average rating of "Moderate Buy" and a consensus price target of $97.44.

Insider Buying and Selling

In other Exact Sciences news, EVP Sarah Condella sold 2,000 shares of the business's stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $70.00, for a total value of $140,000.00. Following the completion of the sale, the executive vice president now directly owns 71,787 shares of the company's stock, valued at approximately $5,025,090. The transaction was disclosed in a filing with the SEC, which is available through this link. In other news, EVP Sarah Condella sold 2,000 shares of the business's stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $70.00, for a total value of $140,000.00. Following the completion of the sale, the executive vice president now owns 71,787 shares in the company, valued at approximately $5,025,090. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Kevin T. Conroy sold 8,271 shares of the stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $59.32, for a total transaction of $490,635.72. Following the sale, the chief executive officer now directly owns 1,299,496 shares of the company's stock, valued at approximately $77,086,102.72. The disclosure for this sale can be found here. In the last ninety days, insiders sold 69,113 shares of company stock valued at $4,165,273. Company insiders own 1.30% of the company's stock.

Exact Sciences Stock Performance

Shares of Exact Sciences stock traded down $2.52 on Friday, hitting $60.96. 2,168,842 shares of the company's stock were exchanged, compared to its average volume of 3,088,935. The stock has a market capitalization of $11.07 billion, a PE ratio of -53.47 and a beta of 1.25. Exact Sciences Co. has a 1 year low of $56.05 and a 1 year high of $100.77. The company has a 50-day simple moving average of $63.42 and a 200-day simple moving average of $65.06. The company has a debt-to-equity ratio of 0.74, a quick ratio of 2.07 and a current ratio of 2.32.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last announced its quarterly earnings results on Wednesday, February 21st. The medical research company reported ($0.27) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.53) by $0.26. Exact Sciences had a negative net margin of 8.17% and a negative return on equity of 6.60%. The company had revenue of $646.89 million for the quarter, compared to the consensus estimate of $638.83 million. During the same period in the previous year, the firm posted ($0.72) EPS. Exact Sciences's revenue for the quarter was up 17.0% compared to the same quarter last year. As a group, equities analysts anticipate that Exact Sciences Co. will post -0.86 EPS for the current year.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.